Mirena IUD Lawsuit Update: The Rottenstein Law Group Responds to Report of Lawsuits’ Effect on Bayer’s Recent Stock Performance
NEW YORK, Feb. 12, 2013 /PRNewswire/ — The Rottenstein Law Group acknowledges a Bloomberg report about German drug manufacturer Bayer’s recent stock losses, which the story attributes to a Mirena lawsuit.
The company saw a 2.8 percent loss following an American woman’s lawsuit (Prendergast v. Bayer Pharmaceuticals Corp., 13-00450, U.S. District Court for the Eastern District of Pennsylvania) against Bayer, according to Bloomberg.* She alleges that the company failed to warn of the risks associated with the Mirena hormonal intrauterine device, such as the risk of ectopic pregnancy and the possibility of device embedment and migration.** As of Feb. 11th, the company stock price slump has persisted.
Rochelle Rottenstein , principal of the Rottenstein Law Group, said she has heard from many women who have discussed similar alleged side effects and risks associated with the Mirena IUD. The Rottenstein Law Group represents clients in Mirena lawsuits.
Read full story at PRNewswire.com: Mirena IUD Lawsuit Update: The Rottenstein Law Group Responds to Report of Lawsuits’ Effect on Bayer’s Recent Stock Performance